Human stem cell treatments are only just emerging in clinical trials. but man's 'best friend' is already benefitting from pain relief and important treatments that are commercialized. And this work in dogs and cats could one day benefit human patients. Dr. Robert Harman, CEO and founder of Vet-Stem, tells the Chicago Tribune's Bruce Japsen about the latest efforts by a stem cell therapy developer to use fat cells for treatments, a therapy gaining momentum in pets and soon to be moving through clinical trials for humans.
Stem Cell Treatments for Man's Best Friend and Man Himself
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Human stem cell treatments are only just emerging in clinical trials. but man's 'best friend' is already benefitting from pain relief and important treatments that are commercialized. And this work in dogs and cats could one day benefit human patients. Dr. Robert Harman, CEO and founder of Vet-Stem, tells the Chicago Tribune's Bruce Japsen about the latest efforts by a stem cell therapy developer to use fat cells for treatments, a therapy gaining momentum in pets and soon to be moving through clinical trials for humans.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
NeuroFrontiers
Navigating Myasthenia Gravis in Adolescents and Young Adults
<p>Navigating Myasthenia Gravis in Adolescents and Young Adults</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?